Belviq, Belviq XR Shows Increase in Cancer

The FDA has requested that the drug manufacturer Eisai, remove their weight-loss drug Belviq (lorcaserin) from the market. A safety clinical trial proves that Belviq and Belviq XR cause an increase in cancer.

Eisai submitted a request to voluntarily withdraw the drug.

After the FDA approved lorcaserin in 2012, they required the drug manufacturer to conduct a  clinical trial to evaluate the risk of cardiovascular problems. As a result, a range of cancer types was reported, with several different types of cancers occurring more frequently in the lorcaserin group. These include pancreatic, colorectal, and lung cancers.

Equifax Breach Deadline Looming

In 2017 it was announced that the credit reporting agency, Equifax, had been hacked, leading to the data breach of millions of Americans. January 22, 2020, is the deadline to file a claim for this breach. Time is running out! You can go to the main Equifax website here and follow the link to the settlement page from there, or you can visit directly at https://www.equifaxbreachsettlement.com/ .

Beware! There are several fraudulent websites out there claiming to be created by Equifax for this settlement.

If you would like more information on this matter or help in filing before the deadline, feel free to Contact Us. 361-882-8284

E-Cigarette/Vaping Outbreak Update

CDC.gov As of December 27, 2019, there have been 2,561 hospitalized cases of lung injury or deaths, associated with the use of e-cigarettes and vaping products reported from all 50 states, the District of Columbia, Puerto Rico and the US Virgin Islands. 55 Deaths were confirmed in 27 states and DC.

No state has gone unaffected by this e-cigarette and vaping outbreak.

Emergency department visits suggest that the outbreak of EVALI or e-cigarette, or vaping product use-associated lung injury, began in June of 2019. Cases have been declining since a peak in September., but have yet to go to levels previously seen before June and remain a constant concern.

Laboratory data support previous findings that vitamin e acetate is closely associated with EVALI.

  • The study analyzed samples from 51 EVALI cases from 16 states and a comparison group of samples from 99 healthier people for vitamin E acetate, plant oils, medium-chain triglyceride(MCT)oil, coconut oil, petroleum distillates, and diluent terpenes.
  • Vitamin E acetate was identified in bronchoalveolar lavage(BAL) fluid samples (fluid samples from the lungs) from 48 of the 51 EVALI patients, but not in the BAL fluid from the healthy comparison group.

National data shows that certain groups of EVALI patients released from the hospital are more likely to be rehospitalized or die.

Groups Challenge EPA

Several environmental and animal protection groups are currently suing the Environmental Protection Agency due to the agency not updating the lacking regulations on slaughterhouses and the horrendous polluting of rivers they cause.

Facilities are currently able to discharge processed wastewater directly into rivers and other waterways and the EPA stated in October that it would not revise federal water standards for plants that did so.

The argument is that the lack of regulation allows for the increase of nitrogen in waterways which leads to the boost of algal blooms. Algae suffocate fish and prevent the growth of plants that naturally filtrate and keep the rivers and streams healthy.

The suit asks for judicial review of the decision to not update regulations that were last revised about 15 years ago and date back decades, leaving many requirements outdated and obsolete due to technological advances.

FDA Warning: Gabapentin/Pregabalin

Neurontin, Gralise, Horizant; brand names for gabapentin and Lyrica, Lyrica CR or pregabalin, are currently being targetted by the FDA for causing serious breathing problems.

Gabapentin and pregabalin are prescribed for conditions such as nerve pain, restless legs syndrome and even seizures.

FDA.gov – “FDA is requiring new warnings about the risk of respiratory depression to be added to the prescribing information of the gabapentinoids. FDA has also required the drug manufacturers to conduct clinical trials to further evaluate their abuse potential, particularly in combination with opioids, because misuse and abuse of these products together is increasing, and co-use may increase the risk of respiratory depression.”

Symptoms to keep an eye out for:

  • Confusion or disorientation
  • Unusual dizziness or lightheadedness
  • Extreme sleepiness or lethargy
  • Slowed, shallow, or difficulty breathing
  • Unresponsiveness, which means a person doesn’t answer or react normally or you can’t wake them up
  • Bluish-colored or tinted skin, especially on the lips, fingers, and toes